Children's Hospital of Philadelphia leads or participates in hundreds of clinical trials. Use this database to learn the purpose of these trials, find out who can participate and more.
111 - 120 of 137
A clinical trial by Amryt Pharma is investigating whether a topical medication, Oleogel-S10, is effective for the treatment of Epidermolysis Bullosa (EB) wounds and is safe for long term use. Oleogel-S10 will be compared to a vehicle gel placebo. The placebo is an identical looking sunflower oil gel that does not contain any active substance. Participants will receive either Oleogel-S10 or vehicle gel for a double-blind study phase of 90 days. The probability that the participant will receive Oleogel-S10 is 50%, which means that they have a 1 in 2 chance of receiving Oleogel-S10. However, in the follow-up phase of the study all participants will be treated with Oleogel S10 for a period of 24 months. The procedures will include blood draws, physical exams, questionnaires, electrocardiograms, wound photography and pregnancy tests (if applicable). This study includes patients with the following subtypes of inherited EB: Junctional EB, Dystrophic EB, and Kindler syndrome.
CHOP is conducting a research study that will help make it possible to do future studies in children and family members both with and without problems with their brain and nervous system. This study involving collecting blood and other types of samples from participants along with medical information. These samples and the information will be stored in a "repository" for an indefinite amount of time. We'll use these tools in the future to create and develop new research studies that may help us find answers to some of these difficult illnesses.
This study is collaborating with the Children’s Hospital of Buffalo to enroll polyarticular and extended oligoarticular juvenile idiopathic arthritis patients. The purpose of this research study is to understand why children are susceptible to rheumatic disease and why some children respond to certain treatments and others do not. The study includes review of your medical record, completion of a study questionnaire, and up to two blood draws.
This study is interested in identifying how the brain reacts to pain both before and after treatment in the intensive RND program. Subjects will undergo noninvasive scans of the brain at the beginning and at the end of their AMPS treatment program. This study will help us identify connections between brain functioning and pain perception in children and teens with AMPS.
Children having spine surgery, aged 12 to less than 17, will be randomized (like flipping a coin to choose) to receive either the study drug EXPAREL or bupivacaine by local injection while they are still asleep at the end of surgery. Both drugs provide pain relief and the study will look at how each controls post-operative pain. 60 patients are needed in this age group. Children ages 6 to less that 12 years of age, having spine or cardiac surgery, would get EXPAREL only by local injection while they are still asleep at the end of surgery. 30 patient participants are needed in this age group. Study procedures include, but are not limited to, a medical surgical history, vital signs, pain scores, neurological assessments, 12 lead electrocardiogram, blood chemistry and hematology samples, (drug screens and alcohol breath testing will be done at the investigator's discretion), Subjects in Group 1 in both age groups will have 8 blood samples drawn for drug levels once they receive the study drug. Subjects will have follow up visits, one occurring at home by a home nursing service, and one follow up visit back to CHOP.
Our team is working on a study to better understand neurological problems, including seizures and developmental delays, that occur in many individuals with HI /HA syndrome. The study involves a one day visit to The Children’s Hospital of Philadelphia and The University of Pennsylvania for a specialized magnetic resonance imaging scan (MRI) of the brain, an electroencephalogram (EEG), blood draw, and completion of questionnaires to evaluate development and behavior. The entire study visit is expected to take about four hours. If you are interested in learning more, please contact us at HIResearch@email.chop.edu.
Prospective data collection will be conducted at CHOP and includes a series of questionnaires and a medical record review including information collected at normally scheduled clinic follow-up visits. Subjects will also participate in study testing at regularly scheduled clinic follow-up visits. This testing will include tests of muscle strength and walking ability,
The purpose of this research study is to collect information over time in juvenile SpA and back pain patients. The information from this study will be used to better understand these conditions in children as well as improve treatment guidelines. The procedures include questionnaires, medical record review, and optional biospecimen contributions (blood and urine).
This is an observational registry of children and young adults with pediatric-onset rheumatic conditions such as juvenile idiopathic arthritis (JIA) and Systemic Lupus Erythematosus (SLE) and SLE-like conditions. The registry will be used to answer questions about how safe medications are, how well medications work, and how well patients do over time. Patients who agree to participate will allow their health information to be used for research, complete a brief questionnaire during their clinic visits, and in some cases, be asked to give a sample of blood, urine, cheek swabs, stool, leftover (from clinical procedure) joint fluid, and leftover (from clinical procedure) tissue biopsy.
The Alterra study is for patients in need of pulmonary valve replacement. The Alterra Adaptive Prestent is a transcatheter stent designed for patients in need of a pulmonary valve replacement who do not want to have to undergo surgery, but have a pulmonary artery poorly suited for current approved transcatheter valves. Surgical placement of a new valve is the most common treatment for a nonworking pulmonary valve, however, there are many risks associated with open heart surgery and it is followed by months of recovery. We are conducting this study to see whether there is a less invasive approach by placing and Alterra Adaptive Prestent to make the pulmonary artery appropriate for transcatheter valve replacement. The Alterra Adaptive Prestent has not been approved by the FDA yet for commercial use and is only available by participating in the study. Please contact Dr. Matthew Gillespie (firstname.lastname@example.org) if you or your patient may be interested in participating in the trial of this device.